This restatement is a severe negative signal for a $5M market cap company. Expect heightened volatility, potential Nasdaq delisting proceedings if the company fails to timely file the amended 10-Q, and a high probability of shareholder litigation.
Price Chart
Executive Summary
HCW Biologics filed an 8-K announcing it can no longer rely on its Q1 2026 financial statements due to a material misstatement in EPS calculation. The company misapplied the two-class method for EPS, overstating basic and diluted EPS by $0.80 per share (reporting $2.19 instead of the correct $1.39). A material weakness in internal controls over complex warrant accounting was identified, and the company will restate the Q1 2026 10-Q. This is a severe credibility event for a micro-cap company with a $5M market cap, significantly increasing litigation and delisting risk.
Key Facts
- Audit Committee concluded Q1 2026 unaudited financial statements should no longer be relied upon due to material EPS misstatement.
- EPS was overstated by $0.80 per share; reported $2.19, correct amount should have been $1.39.
- Error resulted from misapplication of the two-class method for EPS, failing to allocate 36.7% of undistributed earnings to participating warrants.
- A material weakness was identified in internal controls over technical accounting review of complex warrant instruments.
- Company will file an amended 10-Q/A and update related registration statements.
- Auditor Crowe LLP was consulted on the non-reliance determination.
- Company has a market cap of only $5M, making this restatement potentially existential.
Financial Impact
EPS overstated by $0.80 per share on a post-split basis. No total dollar impact on revenue or cash flows disclosed, but the restatement undermines all reported financials for Q1 2026.
Risk Factors
- Shareholder class action lawsuits are highly likely following the restatement.
- Nasdaq may initiate delisting proceedings if the company fails to timely file the amended 10-Q or maintain compliance.
- The identified material weakness in internal controls could lead to further accounting errors in future periods.
- The company's ability to raise capital may be severely impaired given the loss of credibility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-038240 |
| Document: 0001493152-26-038240-index-headers.html | 0001493152-26-038240 |
| Document: 0001493152-26-038240-index.html | 0001493152-26-038240 |
| Document: 0001493152-26-038240.txt | 0001493152-26-038240 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.10 (+12.70%) |
Oct 2, 2026 24d ago | S-1 | $1.64 | awaiting T+60 | — | $1.10 (+32.93%) |
Oct 1, 2026 25d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.10 (+34.91%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.10 (+44.72%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.10 (−48.11%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.10 (+57.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers